Check for updates

Nonribosomal peptides protect *Pseudomonas nunensis* 4A2e from amoebal and nematodal predation†

Sebastian Pflanze, [a] Ruchira Mukherji,[a] Anan Ibrahim, [a] Markus Günther,[a] Sebastian Götze, [a] Somak Chowdhury,[a] Lisa Reimer,[a] Lars Regestein[b] and Pierre Stallforth [*ac]

The rhizosphere is a highly competitive environment forcing bacteria to evolve strategies to oppose their enemies. The production of toxic secondary metabolites allows bacteria to counteract predators. In this study, we describe the anti-predator armamentarium of the soil-derived bacterium *Pseudomonas nunensis* 4A2e. Based on a genome mining approach, we identified several biosynthetic gene clusters coding for nonribosomal peptide synthetases. Generation of gene deletion mutants of the respective clusters shows a loss of defense capabilities. We isolated the novel lipopeptides keanumycin D and nunapeptins B and C, and fully elucidated their structures by a combination of in-depth mass spectrometry experiments, stable isotope labelling, and chemical synthesis. Additionally, investigation of the quorum sensing-dependent biosynthesis allowed us to elucidate parts of the underlying regulation of the biosynthetic machinery. Ecology-inspired bioassays highlight the role of these peptides as a defence strategy against protozoans and led us to find a previously unknown function against the bacterivorous nematode *Oscheius myriophilus*.

Introduction

Microbial predator–prey interactions play an important role in shaping the microbial communities of virtually all ecosystems.[1–3] Predation puts bacterial and fungal communities under a tremendous selection pressure, driving the evolution of traits to resist and overcome grazing. These defence strategies may rely on morphological changes including biofilm formation or increased motility.[2,3] The secretion of toxic metabolites is, however, particularly effective in this regard.[2,3] Especially the production of secondary metabolites including nonribosomal peptides, has been shown to be an effective way to fight various voracious predators such as unicellular eukaryotes and nematodes.[2,4–6] *Pseudomonas* spp., for instance, have been reported to produce the cyclic lipopeptides (CLPs) massetolide and viscosin to resist grazing from the soil-dwelling amoeba *Naegleria americana*;[7] whilst the endosymbiont *Candidatus* Mycoavidus necroximicus protects its fungal host from the

fungivorous nematode *Aphelenchus avenae* by the biosynthesis of anthelmintic benzolactones and a synergistically acting lipodepsipeptide.[8,9] Besides grazing evasion, lipopeptides also play an important role in rhizosphere ecology, as many peptides have been found in either phytopathogenic or plant beneficial pseudomonads.[10,11] One of the best studied CLPs is syringomycin, a chlorinated lipopeptide isolated from the phytopathogen *Pseudomonas syringae* pv. *syringae*.[12] Other members of the syringomycin-like class of CLPs, sometimes referred to as "mycins",[10] include cormycin A from the phytopathogenic *P. corrugata*,[13] but also thanamycin, nunamycin, and brasmycin from disease-suppressive pseudomonads.[14–18] These compounds belong to the family of nonribosomal peptides (NRPs), which are generated by dedicated nonribosomal peptide synthetases (NRPSs). The incorporation of amino acids is not dependent on the ribosome, however, typically multimodular NRPSs allow for the generation of peptides of high structural diversity. Each module contains domains that select amino acids (the adenylation or A domain) and domains that catalyse the amide bond formation (the condensation or C domains). Powerful bioinformatic tools have been developed to both identify the presence of NRPS biosynthetic gene clusters (BGCs) in genomes and the nature of the incorporated amino acids. Details of NRP biosynthesis have been extensively reviewed elsewhere.[19,20]

Interestingly, the biosynthetic gene clusters for mycin biosyntheses are usually tightly co-clustered with BGCs of

[a]Department of Paleobiotechnology, Leibniz Institute for Natural Product Research and Infection Biology – Leibniz-HKI, Beutenbergstrasse 11a, 07745 Jena, Germany. E-mail: pierre.stallforth@leibniz-hki.de

[b]Bio Pilot Plant, Leibniz Institute for Natural Product Research and Infection Biology – Leibniz-HKI, Beutenbergstrasse 11a, 07745 Jena, Germany

[c]Faculty of Chemistry and Earth Sciences, Friedrich Schiller University (FSU), Jena, Germany

another family of NRPs, the "peptins".[10] Members of the peptin family include CLPs such as syringopeptins, suppressing the phytopathogenic fungus *Botrytis cinerea*,[21] as well as thanapeptins and nunapeptin, which have been reported to act on oomycete pathogens.[15,17] Recently, we demonstrated how *Pseudomonas* sp. QS1027 uses a combination of structurally related CLPs, keanumycins and jessenipeptin, to overcome grazing by the model social amoeba *Dictyostelium discoideum*.[22] Interestingly, it has been hypothesised that predation resistance is linked to phytopathogen-suppressive traits, opening potential application in agricultural systems.[23,24] A good example is the work on CLPs of the amphisin family.[11] While anikasin was shown to protect *Pseudomonas fluorescens* HKI0770 from its predator, the social amoeba *Polysphondylium violaceum*, a tensin-like congener supressed *Streptomyces scabies*, the causal organism of potato scab, significantly *in planta*.[25,26] Therefore, to deepen our understanding of the molecular ecology of the antipredator repertoire, we set out to investigate the interaction of pseudomonads and their predators. Here, we describe the isolation, structure elucidation, and functional characterisation of keanumycin D (**1**), nunapeptin B (**2**) and nunapeptin C (**3**), from the amoebicidal *Pseudomonas nunensis* 4A2e, which was co-isolated with the social amoeba *Polysphondylium pallidum* RM1 from forest soil. Bioassays with **1–3** and the co-produced lipopeptide brabantamide A (**4**) against a range of bacterivorous amoebae and an environmental nematode emphasise the importance of those lipopeptides against a broad spectrum of predators; whilst characterisation of gene deletion mutants

of co-clustering LuxR-type proteins and the identification of a quorum sensing mediator shed light on the underlying regulation of NRP biosynthesis. We believe, that our results support our understanding of molecular microbial ecology and may help to engineer suppressive soils.[27]

Results and discussion

Isolation and *in silico* genome analysis of *Pseudomonas nunensis* 4A2e

In order to identify bacterial natural products with anti-predator activity, we co-isolated bacteria (prey) and social amoebae (predators) from forest soil near Jena (50.962 N 11.592 E). Co-cultivation experiments between predators and prey in a 24-well plate format allowed us to subdivide the bacterial isolates in those, which are edible or inedible for these amoebae. The latter were tested for the production of amoebicidal natural products.[28–30] Further investigation of methanolic culture extracts of inedible strains led to the identification of *Pseudomonas nunensis* 4A2e as a producer of anti-amoebal metabolites. Genome sequencing and consecutive genome mining using antiSMASH[31] revealed a region coding for three NRPS BGCs (Fig. 1A and S1†), which is highly similar to a phytopathogen-suppressive genomic island found in the biocontrol strain *Pseudomonas nunensis* In5 (Fig. S2 and S10†).[16,32] Since recent studies have demonstrated a link between predation resistance traits and phytopathogen inhibition, we further examined these NRPS genes.[22,23] The largest


Fig. 1 Nonribosomal lipopeptides encoded in a large genomic island in the genome of *Pseudomonas nunensis* 4A2e. (A) Genomic structure of *nup* BGC, *kea* BGC, and *bra* BGC. (B) Structures of the nonribosomal lipopeptides keanumycin D (**1**), nunapeptin B (**2**) and C (**3**), and brabantamide A (**4**).

BGC codes for three NRPSs (NupA, NupB, NupC) and shares a protein identity of >97% with the respective NRPS genes of the nunapeptin BGC in *P. nunensis* In5. A smaller BGC found in the vicinity of the nunapeptin BGC displays the unique genomic architecture of the syringomycin family BGCs, coding for two NRPSs (KeaA and KeaB) and four additional proteins (KeaC–KeaF), with the latter probably being involved in the tailoring of the characteristic 4-chloro-L-threonine and L-β-*threo*-OH-aspartic acid motif of this natural product class.[33–35] The third NRPS (BraB) contains two modules with specificity for serine and proline, and is flanked by an upstream glycosyltransferase (BraA) and a downstream FAD-dependent monooxygenase (BraC) (Fig. S6 and Tables S3 and S4†) similar to *Pseudomonas* sp. SH-C52, which is also the producer of thanapeptin and thanamycin.[15,36]

Nonribosomal lipopeptides protect against amoebal predators

We proceeded by generating 4A2e mutants with inactivated biosynthetic genes using a markerless allelic replacement strategy.[37] Deletion of the region coding for the adenylation (A) domain and the peptidyl carrier protein (PCP) domain in the first module of each NRPS BGC resulted in three strains: Δ*bra*, Δ*nup*, and Δ*kea*. The resulting gene deletion mutants were co-cultivated with the bacterivorous amoeba *Polysphondylium pallidum* RM1, which was co-isolated with 4A2e. Whilst the Δ*bra* mutant was still inedible, the Δ*nup* and Δ*kea* mutants lost their amoebicidal phenotype and allowed *P. pallidum* RM1 to form characteristic fruiting bodies (Fig. 2A and S15†). This indicated that the metabolites produced by both NRPSs are involved in

the anti-predator resistance of the pseudomonad. Similar results were observed when we co-cultured the bacterial mutants with the laboratory strain *Polysphondylium pallidum* PN500.[38] When tested against other social amoebae such as *Dictyostelium discoideum*[28] and *Dictyostelium purpureum*,[39] only the Δ*kea* mutant proved to be edible. For *Dictyostelium caveatum*,[40] however, Δ*nup* was edible, whilst Δ*kea* still showed no sign of fruiting body formation (Fig. 2B, S16 and S17†). These findings indicate that the presence of both NRPs is necessary to counteract a broader spectrum of protozoal predators and further drew our interest to the structural elucidation of these nonribosomal peptides.

Although the *kea* and *nup* BGCs in 4A2e show a high degree of synteny with those of *P. nunensis* In5 (Fig. S9 and S10†), LCMS analysis of methanolic extracts of wild type 4A2e showed no match with the reported data for nunamycin or nunapeptin, however putative mycin and peptin congeners were detected and identified by comparison of wild type and mutant extracts (Fig. S11†). Due to low production titres of these candidate molecules in the initial amoeba–bacteria co-cultivation medium (SM/5), we conducted an extensive screening to optimise the culture medium for further fermentation experiments, leading to defined cultivation medium (modified Davis medium). Extraction of the supernatant with adsorbent resin and subsequent extensive chromatographic separation yielded four compounds (1–4). It is noteworthy, that careful adjustment of the phosphate concentration substantially influenced the production of **1**.[41,42]

Structure elucidation of keanumycin D

Our recent identification of keanumycins A–C proved to be helpful for structure elucidation of **1** (m/z 1122.5433 $[M+H]^+$).[22,43] Except for keanumycin C, all reported mycins are cyclic lipopeptides. Mild saponification[13] of **1** in MeOH led to the formation of compound with a mass increase of 32 Da (Fig. 3A). This corresponds to the formal addition of methanol, which is in agreement with the hydrolysis of the lactone and the formation of a C-terminal methyl ester. This assumption was supported by subsequent high-resolution tandem mass spectrometry ($HRMS^2$) analysis of the now linearised peptide and allowed us to deduce most of the amino acid sequence. Uncertainty remained about the identity of amino acids AA4 and AA6, which could not be assigned unambiguously by MS^2. Both positions showed a fragment loss of 101 Da, which indicates either a homoserine (Hse) or threonine (Thr) fragment. Bioinformatic prediction of the adenylation domain specificity suggested the incorporation of threonine for module 6 (Fig. S4†), whilst homoserine was the most likely substrate of module 4 (Fig. S5†). Subsequent Marfey's analysis (Fig. S32 and S33†) further supported this assumption, as it revealed the presence of 1x L-Ser, 1x D-Dab, 1x Gly, 1x D-Hse, 1x L-Dab, 1x L-*allo*-Thr, 1x L-β-*threo*-OH-Asp, and 1x 4-Cl-L-Thr,[44] which allowed the unambiguous determination of the configuration of most amino acids, except for the position of L- and D-Dab. Here, closer examination of the genomic architecture of the *kea* BGC suggested that the Dab of position two is D-configured due to


Fig. 2 Edibility assays with selected social amoebae. (A) Co-cultivation of wild type 4A2e and mutant strains with *P. pallidum* RM1. *Klebsiella aerogenes* served as positive control. (B) Edibility of inactivation mutants with a set of social amoebae (Fig. S15–S17†).

A

wild type   Δ*nup*   Δ*kea*

Δ*bra*   *K. aerogenes*

B

	prey			
predator	WT	Δ*nup*	Δ*kea*	Δ*bra*
P. pallidum RM1	inedible	edible	edible	inedible
P. pallidum PN500	inedible	edible	edible	inedible
D. discoideum AX2	inedible	edible	edible	inedible
D. purpureum QSpu1	inedible	edible	edible	inedible
D. caveatum WS695	inedible	edible	inedible	inedible

● edible   ● inedible

Fig. 3 Structure elucidation of keanumycin D. (A) Linearisation of the cyclic lipopeptide by mild hydrolysis, followed by MS^2 analysis to elucidate the amino acid sequence. (B) Identification of the stereochemistry of the 3-hydroxymyristic acid by GCMS analysis of the derivatised fatty acid 5 and comparison with analytical standards 6 and 7.

a downstream C_{dual} domain, which not only condenses the following Gly to the growing peptide chain, but also epimerises the upstream Dab in the process (Fig. 4).[45] The fifth module, however, is adjacent to two downstream ^LC_L domains, that condense an L-configured amino acid to another L-configured amino acid. Therefore, an L-configuration was assigned to Dab at position five. Additionally, we found that module five is lacking an A domain, which is a characteristic of mycin BGCs of the *P. mandelii* group.[10] It was hypothesised for the nunamycin BGC of In5, that the absent A domain in module five is compensated by the Dab-specific A domain of module two.[16] After deducing the structure of the peptide backbone, we focused on the analysis of the lipid motif of the CLP. Based on our HRMS^2 data, we expected the presence of an N-terminal, hydroxylated myristoyl moiety. Acidic hydrolysis, followed by esterification with trimethylsilyldiazomethane and subsequent

derivatisation with (S)-Mosher's acid chloride yielded ester 5, which was then subjected to GCMS analysis. Comparison with synthetic 3-hydroxymyristic acid standards 6 and 7 allowed us to establish the identity of the lipid as (R)-3-hydroxymyristic acid (Fig. 3B and S38†). Thus, 1 was identified as a congener of the recently discovered keanumycins, differing from keanumycin B only by a slightly shorter lipid motif (Fig. 5). Interestingly, although whole-genome phylogenetic analysis shows that 4A2e and In5 share an average nucleotide identity of >96% across their entire genomes (Fig. S8†) and the mycin BGC NRPS core genes share an amino acid sequence identity of >98% (Fig. S10†), they result in slightly different peptide backbones. In contrast, even though 4A2E and QS1027 share low protein identities between KeaA and KeaB (63% and 75%, respectively), they produce CLPs with an identical amino acid sequence and configuration (Fig. 5). More detailed analyses of nonribosomal lipopeptide families have recently been published elsewhere.[10,11,46]

Structure elucidation of nunapeptin B and C

A comparable approach was applied for structure elucidation of peptides 2 and 3. Extensive MS^2 analysis allowed to determine most of the amino acid sequence of both compounds (Fig. S25 and S26†), which is highly similar to nunapeptin isolated from In5 (which we now refer to as nunapeptin A).[16] As a consequence, we named our novel lipopeptides nunapeptins. However, our MS^2 data indicated that 2 and 3 do not have a 3-hydroxyl fatty acid motif, which is usually observed in *Pseudomonas*-derived nonribosomal lipopeptides, but instead bear an N-terminal octanoic acid, which was also detected upon basic hydrolysis of 3 (Fig. S39†). Furthermore, derivatisation of the hydrolysed amino acids with Marfey's reagent yielded the following amino acid composition for 3: 1x D-Pro, 6x D-Ala, 1x L-Ala, 4x D-Val, 2x D-Ser, 1x D-Ile, 1x D-*allo*-Thr, 1x L-Dab, and 1x L-Ile (Fig. S29 and S31†). When we performed the same analysis with 2, we observed 1x L-Val, but no more L-Ile, which is consistent with the mass difference of 14 Da between 2 and 3.


Fig. 4 Domain organisation in the biosynthetic genes of the *nup* and *kea* biosynthetic gene clusters. The depicted stereochemistry and amino acid sequence are experimentally determined. The genes upstream of *keaA* are most likely involved in the tailoring of L-β-*threo*-OH-Asp (*keaF*) and the biosynthesis (*keaC*, *keaD*) and loading (*keaE*) of L-4-Cl-Thr in the last module of KeaB. C_{start}: starter condensation domain; A: adenylation domain; ^LC_L: condensation domain that links an L-amino acid with an L-amino acid; PCP: phosphopantetheinyl carrier protein; C_{dual}: condensation domain with dual epimerisation/condensation activity; TE: thioesterase.

Fig. 5 Structural comparison of selected mycin and peptin family nonribosomal lipopeptides. Amino acid positions highlighted in red are not conserved in the respective CLP group. Lipid: C_x: x indicates the number of carbon atoms in the acyl chain. Ilx: isoleucine or leucine.


Fig. 6 Structure elucidation of the nunapeptins. (A) Stable isotope labelling of **3** by incorporation of L-alanine-2-d$_1$ allowed to identify the position of the single L-alanine in the presence of six D-alanine building blocks in the peptide backbone. (B) Catalytic reduction of **3** to mask dehydrobutyrines and dehydroalanine, followed by ESI-MS^2 analysis resulting in the opening of the lactone and transformation of the former D-*allo*-Thr (AA18) into dehydrobutyrine.

The position of the L-configured amino acids was deduced from the bioinformatic prediction of ^1C_L condensation domains, which were predicted downstream of the Ala- and Dab-specific A domains in module 19 and 20 (Fig. 4). Therefore, we concluded that these positions must be L-configured. For L-Ala19, this assumption was later confirmed by stable isotope labelling. In NRPS biosynthesis, D-amino acids usually originate from L-amino acids, which are epimerised by specialised epimerisation (E) domains or C_{dual} domains with epimerisation activity. Epimerisation of an α-deuterium-labelled amino acid and exchange with a proton from the culture medium results in the loss of the label, whilst L-configured positions would retain the deuterium label, localisable in the final natural product. Hence, we cultivated 4A2e in a defined medium, supplemented with L-alanine-2-d_1, and analysed peptin 3 (Fig. 6A). Comparison of the monoisotopic ion intensity and the intensity of the labelled isotopic ion for peptin 3 showed an increased relative intensity of the isotopologue's ion for the C-terminal part of the peptin sequence (Tables S10 and S11†). Thus, we deduced that an isotope enrichment must have occurred for this part of the molecule. Hence, by combining the bioinformatic prediction and isotope labelling data, we concluded that Ala19 must be L-configured. Having determined the sequence and configuration of the amino acids, we were left with the determination of the ring size of the cyclic part of the lipopeptide. Upon MS^2 analysis, we observed the linearisation of the peptide resulting in the opening of the lactone to give the C-terminal carboxylic acid and a 2,3-unsaturated amino acid.[26] The presence of several unsaturated amino acids in the MS^2 dataset left us uncertain at which position the transformation occurred. Therefore, we masked the unsaturated amino acids in the native peptide by Pd-catalysed hydrogenation, followed by MS^2 analysis of the product (Fig. 6B and S37†). Four positions (AAs 1, 8, 12, and 17) showed an increase of 2 Da as a result of olefin reduction, whilst a single position (AA18) was still identified as Dhb. We concluded that the lactone must be formed between this position (D-allo-Thr18) and the C-terminal carboxylic acid, resulting in a 16-membered ring motif for the nunapeptins (Fig. 6).

Regulation of secondary metabolite biosynthesis

After elucidating the structures of the lipopeptides 1–3, our attention was drawn to putative regulators of the NRPS biosynthesis. Protein BLAST[47] and InterProScan[48] analysis of nearby open reading frames (ORFs) (Tables S3 and S4†) revealed the presence of three genes coding for LuxR-type regulatory proteins (NupR1, NupR2, NunF) and a gene coding for an autoinducer synthase (PcoI). For *Pseudomonas* sp. QS1027 and *Pseudomonas corrugata* CFBP 5454, proteins similar to NupR1, NupR2, and PcoI were described to be involved in the regulation of the NRPS BGCs, whilst in *P. nunesis* In5, $NunF_{In5}$ was reported as a regulator of nunamycin and nunapeptin biosynthesis.[22,49–51] Analysis of gene deletion mutants of 4A2e showed a drastic reduction of the production of 1–3 and also brabantamide A (4), indicating that the respective BGCs are under the influence of the same regulatory network (Fig. S12†). Closer examination of the LuxR-type regulators and a search for

conserved domains within the encoded protein sequences predicted an autoinducer-binding domain (Pfam PF03472) and a DNA-binding helix-turn-helix (HTH) domain (Pfam PF00196) in NupR1, whereas only one HTH domain was predicted for NupR2 and NunF (Fig. S7†). Since PcoI and NupR1 resemble a LuxI/LuxR-type quorum sensing system, we became interested in the putative signalling molecule produced by PcoI. Analysis of wild type supernatants revealed the presence of *N*-hexanoyl homoserine lactone, that was absent in the Δ*pcoI* mutant (Fig. S13†). Therefore, we sought out to re-initiate lipopeptide biosynthesis in the mutant by supplementation with synthetic *N*-hexanoyl-L-homoserine lactone, which was able to restore the production of 1–4 completely (Fig. S14†). Interestingly, *N*-hexanoyl-L-homoserine lactone has also been reported as regulator of peptin and mycin biosyntheses in CFBP 5454 and QS1027, and was also detected in extracts of In5.[22,49,52,53] From an evolutionary point of view it is fascinating how the mycin and peptin NRPS genes in these pseudomonads gradually diversified, whilst the underlying regulatory mechanisms seemingly remained conserved.

In contrast to NupR1, the LuxR-type proteins NupR2 and NunF lack designated autoinducer-binding domains, which makes it likely that their putative ligands are signals other than homoserine lactones, or they act in a ligand independent manner.[54,55] Whilst the nature of potential ligands remains unknown, it has been demonstrated for $NunF_{In5}$ from the biocontrol strain *P. nunensis* In5, that NunF is strongly upregulated in response to glycerol and trehalose, which are fungal- and oomycete-associated molecules but also found in a variety of amoebae.[49,50,56,57] This further strengthens the link between biocontrol traits and resistance to microbial predation,[23,58,59] and has the potential to develop biocontrol formulations of plant beneficial pseudomonads for agricultural application.[60,61]

Bioactivity of 4A2e-derived lipopeptides

The anti-amoebal activity of purified 1–4 was determined against the model social amoeba *Dictyostelium discoideum*, and the human pathogens *Acanthamoeba castellanii* and *Acanthamoeba comandoni* (Table 1 and S6†).[28,62] Interestingly, all peptides showed at least low micromolar activity (IC_{50}) against the amoebae, indicating the importance of the whole genomic region to overcome protozoal grazing.

Nunapeptins suppress bacterivorous nematodes

The activity of these natural products against a variety of protozoans led us to the question, if other microfaunal

Table 1 Anti-amoebal activity of nonribosomal lipopeptides from *Pseudomonas nunensis* 4A2e. Values were determined as half maximal inhibitory concentrations (IC_{50})

| Organism	Keanumycin D (1)	Nunapeptin B (2)	Nunapeptin C (3)	Brabantamide A (4)
D. discoideum	74 nM	5.7 μM	3.1 μM	4.7 μM
A. castellanii	22.8 μM	3.5 μM	2.6 μM	14.6 μM
A. comandoni	20.6 μM	4.0 μM	3.3 μM	8.9 μM

Fig. 7 Propagation of *O. myriophilus* on different mutants of 4A2e. Viable worms were recovered after 10 days at 22 °C and counted. Orange bars indicate mutant with a *nupA* deletion, while blue bars indicate an intact *nupA* gene. Error bars represent standard error ($n = 4$).

predators are also affected by either one of the lipopeptides. For example, bacterivorous nematodes have been extensively studied as microbial predators,[2,63–65] and the production of anthelmintic natural products was described as an effective mean to overcome their predation pressure.[59,66–71] Therefore, we tested 4A2e against the bacterivorous nematode *Oscheius myriophilus* SP1 that was isolated from the same sampling site as 4A2e and *P. pallidum* RM1. Initial tests showed, that nematode cultures co-cultivated with the Δ*nup*Δ*kea*Δ*bra* triple mutant would proliferate, whilst living worms could be hardly recovered when co-cultivated with wild type 4A2e. Encouraged by these results, we set out to determine which specific lipopeptide caused this effect by conducting co-cultivation experiments with a set of 4A2e mutants having several gene deletion combinations. Nematodes and bacteria were co-cultivated for 10 days, which would allow *O. myriophilus* to undergo at least two life cycles and produce offspring. At the end of the experiment, the worms were gently detached from the plates and counted (Fig. 7). Interestingly, the Δ*nup* mutants allowed nematode cultures to thrive, whilst the number of viable worms was drastically reduced in all mutants with an intact *nup* BGC (ESI Table S4;† see github). This indicated, that the products of the *nup* BGC, the nunapeptins, interfere with the viability and propagation of *O. myriophilus*. Although naturally occurring nunapeptin concentrations are most likely lower, we still expect these lipopeptides to contribute to nematode repulsion, especially in combination with other secondary metabolites, such as HCN, which is also produced to some extend by 4A2e under co-cultivation conditions and in several other media (Fig. S40†).[59]

Conclusions

In this study, we applied an ecologically motivated approach to isolate three novel nonribosomal lipopeptides from microbial predator–prey interactions. Bioinformatic as well as extensive MS^2 analyses, combined with synthetic chemistry and stable isotope labelling facilitated the structure elucidation of these

secondary metabolites. A selection of bioassays shed light on the broad-spectrum activity of these metabolites against several microfaunal predators. Eventually, we were able to gain an insight in the intraspecific regulation of these metabolites by a LuxR/LuxI-type quorum sensing system. The structural similarity of these peptides with secondary metabolites that have been described in studies of phytopathogen suppression as well as the high degree of synteny of the respective BGCs raise the question regarding the role such soil-dwelling pseudomonads may play in environmental communities, how they shape the corresponding microbiomes, and how we can use them to engineer suppressive soils.

Data availability

Whole genome sequence data of *Pseudomonas nunensis* 4A2e (bioproject accession no. PRJNA956857), the 16S rDNA sequence of *P. nunensis* 4A2e (OQ830499), and the 18S rDNA sequence data of *P. pallidum* RM1 (OQ842737) and *O. myriophilus* SP1 (OQ832783) have been deposited in Genbank. The codes used to generate the genomic analysis and their corresponding ESI tables can be found in github (**https://github.com/Darcy220606/NRPS-Pnunensis4A2e**).

Author contributions

Sebastian Pflanze: investigation, methodology, conceptualisation, formal analysis, visualisation, writing – original draft. Ruchira Mukherji: investigation, formal analysis, writing – review & editing. Anan Ibrahim: formal analysis, data curation, writing – review & editing. Markus Günther: formal analysis, visualisation, writing – review & editing. Sebastian Götze: investigation, writing – review & editing. Somak Chowdhury: formal analysis, data curation, writing – review & editing. Lisa Reimer: investigation, validation. Lars Regestein: resources. Pierre Stallforth: conceptualisation, funding acquisition, project administration, supervision, writing – original draft and review & editing.

Conflicts of interest

There are no conflicts to declare.

References

1 R. R. Nair, M. Vasse, S. Wielgoss, L. Sun, Y.-T. N. Yu and G. J. Velicer, *Nat. Commun.*, 2019, **10**, 4301.

2 A. Jousset, *Environ. Microbiol.*, 2012, **14**, 1830–1843.

3 C. Matz and S. Kjelleberg, *Trends Microbiol.*, 2005, **13**, 302–307.

4 C. Matz, J. S. Webb, P. J. Schupp, S. Y. Phang, A. Penesyan, S. Egan, P. Steinberg and S. Kjelleberg, *PLoS One*, 2008, **3**, e2744.

5 A. Jousset, E. Lara, L. G. Wall and C. Valverde, *Appl. Environ. Microbiol.*, 2006, **72**, 7083–7090.

6 M. Künzler, *PLoS Pathog.*, 2018, **14**, e1007184.

7 M. Mazzola, I. de Bruijn, M. F. Cohen and J. M. Raaijmakers, *Appl. Environ. Microbiol.*, 2009, **75**, 6804–6811.

8 H. Büttner, S. P. Niehs, K. Vandelannoote, Z. Cseresnyés, B. Dose, I. Richter, R. Gerst, M. T. Figge, T. P. Stinear, S. J. Pidot and C. Hertweck, *Proc. Natl. Acad. Sci. U.S.A.*, 2021, **118**, e2110669118.

9 H. Büttner, S. J. Pidot, K. Scherlach and C. Hertweck, *Chem. Sci.*, 2023, **14**, 103–112.

10 L. Girard, M. Höfte and R. D. Mot, *Crit. Rev. Microbiol.*, 2020, **46**, 397–419.

11 C. Cesa-Luna, N. Geudens, L. Girard, V. De Roo, H. R. Maklad, J. C. Martins, M. Höfte and R. De Mot, *mSystems*, 2023, **8**, e00988.

12 N. Fukuchi, A. Isogai, J. Nakayama, S. Takayama, S. Yamashita, K. Suyama, J. Y. Takemoto and A. Suzuki, *J. Chem. Soc., Perkin Trans.*, 1992, **1**, 1149–1157.

13 A. Scaloni, M. Dalla Serra, P. Amodeo, L. Mannina, R. M. Vitale, A. L. Segre, O. Cruciani, F. Lodovichetti, M. L. Greco, A. Fiore, M. Gallo, C. D'Ambrosio, M. Coraiola, G. Menestrina, A. Graniti and V. Fogliano, *Biochem. J.*, 2004, **384**, 25–36.

14 R. Mendes, M. Kruijt, I. de Bruijn, E. Dekkers, M. van der Voort, J. H. M. Schneider, Y. M. Piceno, T. Z. DeSantis, G. L. Andersen, P. A. H. M. Bakker and J. M. Raaijmakers, *Science*, 2011, **332**, 1097–1100.

15 M. Van Der Voort, H. J. G. Meijer, Y. Schmidt, J. Watrous, E. Dekkers, R. Mendes, P. C. Dorrestein, H. Gross and J. M. Raaijmakers, *Front. Microbiol.*, 2015, **6**, 693.

16 C. F. Michelsen, J. Watrous, M. A. Glaring, R. Kersten, N. Koyama, P. C. Dorrestein and P. Stougaard, *mBio*, 2015, **6**, e0079.

17 C. F. Michelsen, H. Jensen, V. J. Venditto, R. C. Hennessy and P. Stougaard, *PeerJ*, 2015, **3**, e1476.

18 H. Zhao, Y.-P. Liu and L.-Q. Zhang, *Front. Microbiol.*, 2019, **10**, 544.

19 R. D. Süssmuth and A. Mainz, *Angew. Chem., Int. Ed.*, 2017, **56**, 3770–3821.

20 S. L. Wenski, S. Thiengmag and E. J. N. Helfrich, *Synth. Syst. Biotechnol.*, 2022, **7**, 631–647.

21 P. Lavermicocca, N. Sante Iacobellis, M. Simmaco and A. Graniti, *Physiol. Mol. Plant Pathol.*, 1997, **50**, 129–140.

22 S. Götze, R. Vij, K. Burow, N. Thome, L. Urbat, N. Schlosser, S. Pflanze, R. Müller, V. G. Hänsch, K. Schlabach, L. Fazlikhani, G. Walther, H.-M. Dahse, L. Regestein, S. Brunke, B. Hube, C. Hertweck, P. Franken and P. Stallforth, *J. Am. Chem. Soc.*, 2023, **145**, 2342–2353.

23 N. Amacker, Z. Gao, B. C. Agaras, E. Latz, G. A. Kowalchuk, C. F. Valverde, A. Jousset and S. Weidner, *Front. Microbiol.*, 2020, **11**, 614194.

24 S. Weidner, E. Latz, B. Agaras, C. Valverde and A. Jousset, *Plant Soil*, 2017, **410**, 509–515.

25 S. Götze, R. Herbst-Irmer, M. Klapper, H. Görls, K. R. A. Schneider, R. Barnett, T. Burks, U. Neu and P. Stallforth, *ACS Chem. Biol.*, 2017, **12**, 2498–2502.

26 A. Pacheco-Moreno, F. L. Stefanato, J. J. Ford, C. Trippel, S. Uszkoreit, L. Ferrafiat, L. Grenga, R. Dickens, N. Kelly, A. D. Kingdon, L. Ambrosetti, S. A. Nepogodiev, K. C. Findlay, J. Cheema, M. Trick, G. Chandra, G. Tomalin, J. G. Malone and A. W. Truman, *eLife*, 2021, **10**, e71900.

27 R. Gómez Expósito, I. de Bruijn, J. Postma and J. M. Raaijmakers, *Front. Microbiol.*, 2017, **8**, 2529.

28 R. Froquet, E. Lelong, A. Marchetti and P. Cosson, *Nat. Protoc.*, 2009, **4**, 25–30.

29 M. Klapper, S. Götze, R. Barnett, K. Willing and P. Stallforth, *Angew. Chem., Int. Ed.*, 2016, **55**, 8944–8947.

30 J. Arp, S. Götze, R. Mukherji, D. J. Mattern, M. García-Altares, M. Klapper, D. A. Brock, A. A. Brakhage, J. E. Strassmann, D. C. Queller, B. Bardl, K. Willing, G. Peschel and P. Stallforth, *Proc. Natl. Acad. Sci. U.S.A.*, 2018, **115**, 3758–3763.

31 K. Blin, S. Shaw, A. M. Kloosterman, Z. Charlop-Powers, G. P. van Wezel, M. H. Medema and T. Weber, *Nucleic Acids Res.*, 2021, **49**, W29–W35.

32 F. Ntana, R. C. Hennessy, A. Zervas and P. Stougaard, *Int. J. Syst. Evol. Microbiol.*, 2023, **73**, 005700.

33 F. H. Vaillancourt, J. Yin and C. T. Walsh, *Proc. Natl. Acad. Sci. U.S.A.*, 2005, **102**, 10111–10116.

34 G. M. Singh, F. H. Vaillancourt, J. Yin and C. T. Walsh, *Chem. Biol.*, 2007, **14**, 31–40.

35 G. M. Singh, P. D. Fortin, A. Koglin and C. T. Walsh, *Biochemistry*, 2008, **47**, 11310–11320.

36 Y. Schmidt, M. van der Voort, M. Crüsemann, J. Piel, M. Josten, H.-G. Sahl, H. Miess, J. M. Raaijmakers and H. Gross, *ChemBioChem*, 2014, **15**, 259–266.

37 L. R. Hmelo, B. R. Borlee, H. Almblad, M. E. Love, T. E. Randall, B. S. Tseng, C. Lin, Y. Irie, K. M. Storek, J. J. Yang, R. J. Siehnel, P. L. Howell, P. K. Singh, T. Tolker-Nielsen, M. R. Parsek, H. P. Schweizer and J. J. Harrison, *Nat. Protoc.*, 2015, **10**, 1820–1841.

38 A. J. Heidel, H. M. Lawal, M. Felder, C. Schilde, N. R. Helps, B. Tunggal, F. Rivero, U. John, M. Schleicher, L. Eichinger, M. Platzer, A. A. Noegel, P. Schaap and G. Glöckner, *Genome Res.*, 2011, **21**, 1882–1891.

39 S. Basu, P. Fey, Y. Pandit, R. Dodson, W. A. Kibbe and R. L. Chisholm, *Nucleic Acids Res.*, 2012, **41**, D676–D683.

40 C. Schilde, H. M. Lawal, K. Kin, I. Shibano-Hayakawa, K. Inouye and P. Schaap, *Mol. Phylogenet. Evol.*, 2019, **134**, 66–73.

41 D. C. Gross, *J. Appl. Bacteriol.*, 1985, **58**, 167–174.

42 J. H. Zhang, N. B. Quigley and D. C. Gross, *Appl. Environ. Microbiol.*, 1997, **63**, 2771–2778.

43 S. Götze and P. Stallforth, *Org. Biomol. Chem.*, 2020, **18**, 1710–1727.

44 H. K. Webb and R. G. Matthews, *J. Biol. Chem.*, 1995, **270**, 17204–17209.

45 S. Dekimpe and J. Masschelein, *Nat. Prod. Rep.*, 2021, **38**, 1910–1937.

46 S. Götze and P. Stallforth, *Nat. Prod. Rep.*, 2020, **37**, 29–54.

47 C. Camacho, G. Coulouris, V. Avagyan, N. Ma, J. Papadopoulos, K. Bealer and T. L. Madden, *BMC Bioinf.*, 2009, **10**, 421.

48 T. Paysan-Lafosse, M. Blum, S. Chuguransky, T. Grego, B. L. Pinto, G. A. Salazar, M. L. Bileschi, P. Bork, A. Bridge, L. Colwell, J. Gough, D. H. Haft, I. Letunić, A. Marchler-Bauer, H. Mi, D. A. Natale, C. A. Orengo, A. P. Pandurangan, C. Rivoire, C. J. A. Sigrist, I. Sillitoe, N. Thanki, P. D. Thomas, S. C. E. Tosatto, C. H. Wu and A. Bateman, *Nucleic Acids Res.*, 2023, **51**, D418–D427.

49 R. C. Hennessy, C. B. W. Phippen, K. F. Nielsen, S. Olsson and P. Stougaard, *MicrobiologyOpen*, 2017, **6**, e00516.

50 L. Christiansen, K. S. Alanin, C. B. W. Phippen, S. Olsson, P. Stougaard and R. C. Hennessy, *Appl. Environ. Microbiol.*, 2020, **86**, e01284.

51 G. Licciardello, A. Caruso, P. Bella, R. Gheleri, C. P. Strano, A. Anzalone, E. A. Trantas, P. F. Sarris, N. F. Almeida and V. Catara, *Front. Microbiol.*, 2018, **9**, 521.

52 G. Licciardello, I. Bertani, L. Steindler, P. Bella, V. Venturi and V. Catara, *FEMS Microbiol. Rev.*, 2007, **61**, 222–234.

53 G. Licciardello, C. P. Strano, I. Bertani, P. Bella, A. Fiore, V. Fogliano, V. Venturi and V. Catara, *J. Biotechnol.*, 2012, **159**, 274–282.

54 C. Bez, S. Covaceuszach, I. Bertani, K. S. Choudhary and V. Venturi, *mSphere*, 2021, **6**, e01322.

55 C. Bez, A. M. Geller, A. Levy and V. Venturi, *mSystems*, 2023, e01039.

56 L. A. Temesvari, G. Klein and D. A. Cotter, *Mycologia*, 1996, **88**, 819–830.

57 R. Deslauriers, H. C. Jarrell, R. A. Byrd and I. C. P. Smith, *FEBS Lett.*, 1980, **118**, 185–190.

58 M. S. Müller, S. Scheu and A. Jousset, *PLoS One*, 2013, **8**, e66200.

59 N. Neidig, R. J. Paul, S. Scheu and A. Jousset, *Microb. Ecol.*, 2011, **61**, 853–859.

60 S. Tienda, C. Vida, E. Lagendijk, S. de Weert, I. Linares, J. González-Fernández, E. Guirado, A. de Vicente and F. M. Cazorla, *Front. Microbiol.*, 2020, **11**, 1874.

61 A. Bejarano and G. Puopolo, in *How Research Can Stimulate the Development of Commercial Biological Control Against Plant Diseases*, ed. A. De Cal, P. Melgarejo and N. Magan, Springer International Publishing, Cham, 2020, vol. 21, pp. 275–293.

62 M. R. Mungroo, R. Siddiqui and N. A. Khan, *Folia Microbiol.*, 2021, **66**, 689–699.

63 N. Neidig, A. Jousset, F. Nunes, M. Bonkowski, R. J. Paul and S. Scheu, *Funct. Ecol.*, 2010, **24**, 1133–1138.

64 J. Zheng, F. Dini-Andreote, L. Luan, S. Geisen, J. Xue, H. Li, B. Sun and Y. Jiang, *mBio*, 2022, **13**, e03293.

65 L. K. Carta, *J. Nematol.*, 2000, **32**, 362–369.

66 M. Nandi, C. Selin, A. K. C. Brassinga, M. F. Belmonte, W. G. D. Fernando, P. C. Loewen and T. R. de Kievit, *PLoS One*, 2015, **10**, e0123184.

67 P. Burlinson, D. Studholme, J. Cambray-Young, D. Heavens, J. Rathjen, J. Hodgkin and G. M. Preston, *ISME J.*, 2013, **7**, 1126–1138.

68 W. Zhou, J. Vergis and T. Mahmud, *J. Nat. Prod.*, 2022, **85**, 590–598.

69 E. Pradel, Y. Zhang, N. Pujol, T. Matsuyama, C. I. Bargmann and J. J. Ewbank, *Proc. Natl. Acad. Sci. U.S.A.*, 2007, **104**, 2295–2300.

70 F. Ballestriero, J. Nappi, G. Zampi, P. Bazzicalupo, E. Di Schiavi and S. Egan, *Sci. Rep.*, 2016, **6**, 29284.

71 J. E. E. U. Hellberg, M. A. Matilla and G. P. C. Salmond, *Front. Microbiol.*, 2015, **6**, 137.